Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Tecentriq/Cabometyx Cuts Risk of Disease Progression or Death by 35% in CRPC
A combination therapy pairing Takeda Pharmaceutical’s tyrosine kinase inhibitor Cabometyx (cabozantinib) and Chugai Pharmaceutical’s PD-L1 inhibitor Tecentriq (atezolizumab) reduced the risk of disease progression or death by 35% in certain prostate cancer patients, according to the latest data update. The…
To read the full story
Related Article
- Tecentriq/Cabometyx Combo Extends PFS in Prostate Cancer Trial: Takeda
August 23, 2023
- Chugai, Takeda to Join Global PIII of Tecentriq/Cabometyx Combo in Japan
September 11, 2020
BUSINESS
- Shionogi/F2G’s Novel Antifungal Makes Mark, New Option in Resistant Cases
June 19, 2026
- Axcelead Joins Lilly’s TuneLab AI Drug Discovery Platform
June 19, 2026
- Create BioVentures Sets Sail as Drug Discovery Bridge Builder
June 19, 2026
- Merck Japan Expands Fertility Benefits, Raises Lifetime Cap to 18 Million Yen
June 19, 2026
- Santen CEO Paid 251 Million Yen in FY2025, COO Joins Disclosure List
June 19, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…